Trading Profile: BioMarin Pharmaceutical, Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises approved products and multiple investigational product candidates. Its approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of genetic disease called mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used for the treatment of mucopolysacch...
»»» Detailed Company Profile & Chart
BioMarin Pharmaceutical Inc current day financials: 2024-04-23 09:00:18pm| Symbol | Name | Purchase price | Last Price | Change | % Change |
|---|---|---|---|---|---|
| 0.00 | |||||
Recent BMRN News from Yahoo Finance & Seeking Alpha
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season? »
BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect »
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says »
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics »
Besides Wall Street's top -and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline »
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Older Archived News BioMarin Pharmaceutical Inc
- Insider Trading Alert - BRT, BMRN And CSGS Traded By Insiders.
- BMRN, INCY And ALXN, Pushing Drugs Industry Downward.
- BioMarin Pharmaceutical (BMRN) Earnings Report: Q4 2015 Conference Call Transcript.
- Biomarin Pharmaceutical (BMRN) Down In After-Hours Trading.
- Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock.
- Today's Weak On High Volume Stock: Biomarin Pharmaceutical (BMRN).
- Pharma Investors Look for Lessons After BioMarin FDA Defeat.
- BioMarin Fails to Win Approval for Drug to Treat Duchenne.
- Today's Dead Cat Bounce Stock Is Biomarin Pharmaceutical (BMRN).
- The Top 5 Large Cap Biotechnology Stocks for 2016 (AMGN, BIIB).Load More News...
